CD1A and psoriasis: These data offer an alternative model of psoriasis pathogenesis in which lipid-specific CD1a-reactive T cells contribute to psoriatic inflammation, suggesting that cPLA2δ inhibition or CD1a blockade may have potential for treatment of psoriasis.